retatrutide weight loss trial retatrutide Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released phase 2 results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide produces up to 30.3%

Best Practices Only used under the supervision of the veterinary

Hard-boil 12 eggs

These theories suggest that targeted interventions on specific biological processes and functions that decline with chronological age may attenuate biological aging (Guo et al., 2022)

Yes conditions such as hypothyroidism, Cushing's syndrome, PCOS, and obstructive sleep apnoea can blunt weight loss responses

doi: 10.1126/science.1170116 220 TahilianiM.MeiP.FangR.LeonorT.RutenbergM.ShimizuF.et al

Rapid weight loss at this rate suggests either dramatic overdosing, an concurrent illness affecting weight, or dehydration masquerading as fat loss